Anti-Asthmatics And COPD Drugs Market Key Drivers, Trends, Growth, and Outlook 2024-2033

"The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company presents an extensive market research report on the Anti-Asthmatics And COPD Drugs Global Market Report 2024, furnishing businesses with a competitive edge through a detailed examination of the market structure, encompassing estimates for various segments and sub-segments.

Furthermore, the report highlights on emerging trends, significant drivers, challenges, and opportunities, providing all necessary data for thriving in the industry. This report market research offers a comprehensive perspective, including an in-depth analysis of the present and future scenarios within the industry.

Market Sizing:

The anti-asthmatics and copd drugs market size has grown strongly in recent years. It will grow from $76.16 billion in 2023 to $81.41 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to include increased prevalence of respiratory diseases, increased incidence of tobacco smoking, global warming, geriatric population, emerging markets, new methods for drug discovery, rise in healthcare expenditure.

The anti-asthmatics and copd drugs market size is expected to see strong growth in the next few years. It will grow to $104.1 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increased popularity of e-cigarettes/ vaping, rising obesity levels, technology, large pool of undiagnosed population, use of anti-asthmatics and copd drugs to treat covid-19 patients, increasing consumption of fats . Major trends in the forecast period include developing probiotic drugs for asthma to offer a full range of available treatments, developing anti-il-5 drugs to expand their business portfolio, launching new innovative products to focus on establishing their market position and sustain their position among intense competition in the market, invest more in developing bioelectric medicines to improve asthma care, focus on increasing the number of collaborations to expand their business portfolio, explore opportunities in personalized medicine to counter the intense competition and provide customized treatment to individuals, invest in aerosol respiratory drugs for better efficacy, investing in biomarkers to produce more effective drugs in a smaller time frame, focus efforts on investing in generic drugs to counter the intense competition, developing combination drugs to offer better result, developing biologics to capitalize on the growing demand for biologics..

Request for free sample report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp

Key Market Players:

Major companies operating in the anti-asthmatics and copd drugs market report are GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Sumitomo Dainippon Pharma Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Shanghai Acebright Pharmaceuticals Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd, Hanmi Pharmaceutical, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, GSK, Shanghai Anovent Pharma, China Meheco Group Co. Ltd., Lupin Limited, ASGEN Pharmaceutical Co. Ltd, Abbott Laboratories, Pfizer, Vectura Group, Bristol Myers Squibb, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Bayer, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Cipla Medpro South Africa (Pty) Limited, Aspen Nigeria

Market Drivers:

Modifiable risk factors including smoking, lack of physical exercise, and unhealthy eating habits drive the Asthma and COPD drugs market. Even though there is a decreasing trend in smoking prevalence globally, developing countries such as China, India, Indonesia, and Nigeria among others have increasing smoking prevalence. For instance, the number of tobacco smokers is set to increase by 24 million in Indonesia and by 7 million in Nigeria by 2025, and more than 40% of global cigarette consumption is concentrated in China. Consumption of fats including saturated fatty acids which is a risk factor for Asthma and COPD is more in high-income countries including the USA and Europe. According to WHO, in developed countries, more than 35% of total energy requirement is derived from fats when compared to

"Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

"Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps"

This release was published on openPR.